vimarsana.com

Page 3 - இந்தியன் நிறுவனம் ஆஃப் இரசாயன தொழில்நுட்பம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ministry of Science & Technology

IICT Hyderabad, Lee Pharma to Make COVID Drug 2-DG

Lee Pharma Ltd. announced that it has entered into a non-exclusive licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT) for process know-how for the synthesis of 2-DG (2-Deoxy-D-Glucose). IICT, a constituent laboratory of the Council of Scientific and Industrial Research (CSIR) and Lee Pharma, an integrated pharmaceutical company,

IICT, Suven Pharma join hands to make anti-COVID drugs

CSIR-IICT, Lee Pharma in licensing agreement for synthesis of 2-DG

CSIR-IICT, Lee Pharma in licensing agreement for synthesis of 2-DG CSIR-IICT, Lee Pharma in licensing agreement for synthesis of 2-DG 09 June 2021 | News Lee Pharma will manufacture and commercialise the 2-DG sachets from their formulation facility located at SEZ, Duvvada www.shutterstock.com shIndian Institute of Chemical Technology, (IICT), a constituent laboratory of CSIR and Lee Pharma, an integrated pharmaceutical company, based in Hyderabad have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Recently, 2-DG developed by DRDO and Dr Reddy’s Laboratories has received approval for use in COVID-19 patients. It has been found to help speed up recovery and reduce oxygen dependence and Dr Reddy’s Laboratories has launched the drug in the form of sachets.

CSIR-IICT licenses process knowhow for synthesis of 2-Deoxy-D-Glucose to Lee Pharma Ltd

Share New Delhi: Indian Institute of Chemical Technology, (IICT), a constituent laboratory of CSIR and Lee Pharma, an integrated pharmaceutical company, based in Hyderabad have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Recently, 2-DG developed by DRDO and Dr Reddy’s Laboratories has received approval for use in Covid-19 patients. It has been found to help speed up recovery and reduce oxygen dependence and Dr. Reddy’s Laboratories has launched the drug in the form of sachets. Lee Pharma informed that they would file the application for getting the approval from DCGI, New Delhi. Lee Pharma will manufacture and commercialize the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam, Andhra Pradesh, which has the accreditations, by global regulatory agencies.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.